drugset / Trial / NCT00698009
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
NaSingle-groupOpen-labelTreatment
Summary
Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2). Secondary: * Quantification of cytokine levels; * Assessment of NK cell immunophenotype and function.
Timeline
- Start
- 2008-06
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | — | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 5e+06 unknown | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 1e+07 iu | Subcutaneous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 12 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |